Gynecologic Oncology

Papers
(The H4-Index of Gynecologic Oncology is 38. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Targeting master regulators with general transcription inhibitors in clear cell ovarian cancer104
Patient-reported post-discharge opioid use after abdominal gynecologic surgery in an Enhanced Recovery After Surgery (ERAS) program (004)101
Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery101
Ovarian and uterine carcinosarcoma cell lines show preclinical sensitivity to BAY 1895344, a novel ataxia-telangiectasia and Rad3-related (ATR) kinase inhibitor (011)92
Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes80
Taking the ‘first steps’ to a healthier lifestyle: The initial acceptability and feasibility of a health behavior intervention for endometrial cancer survivors with obesity and their social support ne79
Leave it in the past: Primary treatment modality for high-grade epithelial ovarian cancer does not affect secondary cytoreduction outcomes (173)77
Short-term hormone replacement therapy in BRCA mutation carriers and risk of breast cancer: A nationwide study in Korea (1155)75
Prognostic factors of survival in women with recurrent platinum-resistant epithelial ovarian cancer (1171)63
Predictors of long-term response in prospective phase II trial of levonorgestrel intrauterine device for atypical hyperplasia and early endometrial cancer (1247)62
TOGETHER Care: PatienT-tailOred GynEcologic Oncology posT discHargE caRe (290)61
Quality-adjusted survival in women with gynecologic malignancies receiving IMRT after surgery: A Ppatient Rreported Ooutcome study of NRG oncology's RTOG 120361
Adverse postoperative outcomes associated with perioperative blood transfusion in gynecologic oncology surgery: a National Surgical Quality Improvement Program analysis (467)58
Diversifying clinical trials: Does presentation at gynecologic oncology tumor board increase equitable access to clinical trials for Black and LatinX patients? (2205)56
Improving the cancer survivorship journey: Developing a survivorship care transition model for rural and underserved low risk breast and gynecologic cancer patients (511)55
Clinical impact of low-volume lymph node metastases in early- stage cervical cancer: A comprehensive meta-analysis (504)55
Mitigating disparity? Recurrence rates and palliative care referrals by race and ethnicity across a large urban health system (514)54
Role of lymphadenectomy for apparent early-stage low-grade serous ovarian carcinoma (529)54
Impact of increased cycles of neoadjuvant chemotherapy on interval debulking surgery outcomes (541)52
The impact of bowel preparation on surgical site infection rates in gynecologic oncology surgery, post-hoc analysis from a randomized controlled trial (550)50
Pattern of recurrence and survival: Comparative analysis of robotic radical hysterectomy with uterine manipulator versus without uterine manipulator and or vaginal cerclage in treatment of stage IB ce49
Creation of a surgical service line to treat patients with recurrent gynecologic cancer with curative intent: Complex oncologic multidisciplinary pelvic surgery (COMPS) (559)48
Multi-omic and clinical data analysis of pre-menopausal women under 45 years of age diagnosed with endometrial cancer and enrolled in the ASAP trial (2154)48
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? – A geospatial analysis (2127)47
Endometrial stripe thickness at the time of diagnosis of uterine papillary serous carcinoma in black patients (2137)46
Impact of venous thromboembolism on timing and outcomes of interval debulking surgery among patients treated with neoadjuvant chemotherapy for advanced ovarian cancer (370)45
Prediction of ovarian cancer with deep machine-learning and alternative splicing (2167)45
Metastatic site-specific prognosis of women with stage IVB cervical cancer (345)45
Effect of sentinel lymph node isolated tumor cells on recurrence free survival in patients with mismatch repair proficient vs. deficient stage I/II endometrioid endometrial adenocarcinoma (173)43
Ketogenic Diet Promotes Epithelial Ovarian Cancer Progression and Alters Tumor Gene Expression in-vivo (104)43
Molecular profiling of gestational trophoblastic neoplasia: Identifying therapeutic targets (167)42
Development of a molecular and clinical evidence-based algorithm for selecting optimal precision therapeutic strategy for patients with ovarian carcinoma (157)42
Corrigendum to “Gemogenovatucel-T (Vigil) immunotherapy demonstrates clinical benefit in homologous recombination proficient (HRP) ovarian cancer” [Gynecologic Oncology Volume 161, Issue 3, June 2021,41
Impact of COVID-19 on gynecologic oncology patients: an SGO COVID-19 and Gynecologic Cancer Registry study (050)41
The role of adjuvant radiation therapy in older patients with node-positive vulvar cancer: A national cancer database analysis41
Corrigendum to “Chemotherapy response score (CRS) as a surrogate marker for homologous recombination deficiency (HRD) based on loss of heterozygosity (LOH) in high grade serous ovarian cancer (HGSOC) 39
Defining “enlarged” sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?38
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group38
Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial38
0.73536205291748